Topics: C-Reactive Protein | Coronavirus | COVID19 | CRP | Lamictal | Lamotrigine | Medical Comorbidities | Neurology | Neuroscience in Psychiatry | Traumatic Brain Injury (TBI)

Pandemics create a long list of psychosocial stressors, but COVID-19 also has direct effects on the CNS. Neuropsychiatric syndromes can develop after the respiratory illness resolves. Paul Riordan reviews the cardinal symptoms to look for after a COVID infection.

Topics: Bipolar Disorder | Bipolar II | Coronavirus | COVID19 | Lithium | Mania | Mood Stabilizers | Pharmacology | Pharmacology Tips | Psychopharmacology | Psychopharmacology Tips

Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.

Topics: Antipsychotics | Delusional Disorder | Pimozide | Psychosis | Psychotic Depression

Delusional disorder may be in the psychotic chapter, but it doesn’t respond to antipsychotics like we’d expect. Joseph Pierre reviews how to use them, which ones to avoid, and how to enhance your therapeutic relationship with this population.

Topics: Bipolar Disorder | Lithium | Mania | Mood Stabilizers | Oxcarbazepine | Pharmacology | Psychopharmacology | Research | Research Update

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.

On July 13, 2020, SAMHSA modernized the law to allow disclosure without patient consent during emergencies that result from a natural disaster. COVID-19 is included alongside hurricanes and floods in the list, though the opioid crisis is not.

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.